Graham G. Walmsley's Form 4 filing
Akero Therapeutics, Inc. (AKRO) · filed Dec 11, 2023
- Accession no.
- 0000950170-23-069509
- Filed
- Dec 11, 2023
- Trade date
- Dec 8, 2023
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $1.98M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Graham G. WalmsleyCIK 0001777517 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 8, 2023 | Common Stock | PPurchaseAcquired | +50,000 | $19.80 | +$990,000 | 750,000 | Indirect | |
| Dec 8, 2023 | Common Stock | PPurchaseAcquired | +50,000 | $19.85 | +$992,500 | 800,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.